Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors.
Dublin, Ohio–based Navidea ‘s chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions, effective immediately.
The board appointed Alexander L. Cappello and John K. Scott, Jr., both existing members of the board, as the chair and vice chair of the board, respectively, according to a news release. The changes were announced following the company’s 2021 annual meeting of stockholders.
Additionally, Cappello was appointed to the company’s audit committee alongside existing members Amit Bhalla (chair) and Malcolm Witter. The board appointed both Cappello and Scott to the compensation, nominating and governance (CNG) committee and appointed Witter as chair of that committee.
“We thank both Kathy and Claudine for their service on the board and the valuable insights they have provided over the years,” Navidea CEO Jed Latkin said in the release. “With a combined 60 years of experience in the clinical space their contributions helped shape both the diagnostic and therapeutic direction of the company. We wish them the best in their future endeavors.”
Navidea develops precision immunodiagnostic agents and immunotherapeutics, including dextran-based drug delivery vehicles deliver potent drugs to the cells where the virus is multiplying, targeting specific macrophages that replicate.